AF7- Administration of elexacaftor/tezacaftor/ivacaftor in a CFTR carrier mother for treatment of meconium ileus in a F508del fetus with extension of therapy into the postpartum period
PF1- The comeback kid: Pulmonary and pancreatic restoration in a school-aged child with cystic fibrosis on long-term highly effective modulator therapy
PF7- A case of recurrent massive hemoptysis and bronchiectasis in a toddler with cystic fibrosis treated with bronchial artery embolization and lobectomy
Speaker: Beth A. Smith, MD – Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Speaker: Stephanie S. Filigno, PhD – Cincinnati Children's Hospital Medical Center, Divisions of Behavioral Medicine and Clinical Psychology & Pulmonary Medicine
W19.1- Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study
W19.4- The CF Home Sputum-Induction Trial (CF-HomeSpIT) : Primary outcome data for early morning sputum-induction at home compared to same-day sputum-induction in clinic.
Location: Ballroom 3
Speaker: Julian T. Forton – The Children's Hospital for Wales, Cardiff, UK
10:15 AM - 12:15 PM PDT
W19.5- Evaluating the clinical utility of oropharyngeal swabs from children with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor using shotgun metagenomics
W20.1- Comparative clinical outcomes of Trikafta® versus bioequivalent ETI formulations in the management of Cystic Fibrosis in adults: a real world experience
W20.2- A Phase II study (CLAIRAFLY®) evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of the DPP1 (CatC) inhibitor BI 1291583 in cystic fibrosis: Effects of CFTR modulator therapy use
W20.4- Nutritional decline and glycemic variability as early clinical indicators in pediatric cystic fibrosis patients undergoing CGM: a retrospective cohort analysis
W24.3- Pilot study of the PACE-CF Pain Acknowledgement, Coping, and Empowerment intervention for adults
Location: 423-425
Speaker: Amanda S. Bruce – University of Kansas Medical Center
10:15 AM - 12:15 PM PDT
W24.4- Stress less, live more: Coping and Learning to Manage Stress (CALM) telehealth sessions help alleviate severe depression and anxiety symptoms in adults with CF
W25.2- Financial & administrative impacts on people with cystic fibrosis, pharmacists, and pharmacy technicians at CFF-accredited care centers following changes in pharmaceutical limited distribution network
W25.4- Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age
Location: Signature Room
Speaker: Ngoc Hoa Truong, n/a – URP7323, Pharmacologie Et Évaluation Des Thérapeutiques Chez L'enfant Et La Femme Enceinte Université Paris Cité, Paris, France.
10:15 AM - 12:15 PM PDT
W25.5- Modeling a single variable-time measurement of Elexacaftor/Tezacaftor/Ivacaftor in adults
Location: Signature Room
Speaker: Silvia Caceres, MS – University of North Carolina- Chapel Hill/ National Jewish Health
W26.3- Evaluation of testosterone levels in males with Cystic Fibrosis before and after initiation of Elexacaftor/Tezacaftor/Ivacaftor: Data from the PROMISE study
W26.4- Pregnancy and early parenthood does not have a detrimental impact on CF-health status in women under a dedicated CF Maternal Health Service in the elexacaftor/tezacaftor/ivacaftor era
W28.1- An evaluation of fecal metabolomics and markers of intestinal integrity in individuals with advanced cystic fibrosis liver disease (aCFLD) and the effect of Elexacaftor-Tezacaftor-Ivacaftor (ETI)
Location: Ballroom 2
Speaker: Nicole Green, M.D. – Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA, USA
10:15 AM - 12:15 PM PDT
W28.2- Multivariate classification of gut symptoms in people with CF identifies four phenotypes
Changes in sweat chloride concentrations following CFTR modulator treatment and association with antibiotic usage in adolescents and adults with cystic fibrosis
Location: Theater A Exhibit Hall
Speaker: Sivagurunathan Sutharsan – Department of Pulmonary Medicine, Division of Cystic Fibrosis, University Medicine Essen -Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
2:30 PM - 4:00 PM PDT
Sweat sodium: chloride ratio differs in people with CF by CFTR modulator treatment status
Evaluation of the variability of exhaled breath profiles for the detection of Pseudomonas aeruginosa infections in cystic fibrosis: A longitudinal study
Maximizing benefits with early CFTR modulator treatment: Lower sweat chloride is associated with improved clinical outcomes in children aged 6 to 11 years
Location: Theater A Exhibit Hall
Speaker: Rachel Linnemann, MD – Department of Pediatrics, Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine
2:30 PM - 4:00 PM PDT
Parameter D: A novel biomarker to detect small airway disease through spirometry in cystic fibrosis
S18.4- Weight Inclusive Approach to Counseling Patients and Caregivers
Location: Flex A
Speaker: Stephanie S. Filigno, PhD – Cincinnati Children's Hospital Medical Center, Divisions of Behavioral Medicine and Clinical Psychology & Pulmonary Medicine
2:30 PM - 4:30 PM PDT
S19--Don’t Sweat It: Navigating the Relationship Between Sweat Chloride & Clinical Outcomes in CF
S19.3- Sweat Signals: Use of Sweat Chloride in Clinical Trials of CFTR Modulators
Location: 435
Speaker: Rachel Linnemann, MD – Department of Pediatrics, Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine
2:30 PM - 4:30 PM PDT
S19.4- Promise and Pitfalls in Sweat Chloride Use for Clinical Monitoring and Therapeutics Development
Speaker: Nicole Green, M.D. – Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA, USA